“VYXEOS is a valuable therapeutic option for patients with this complex, rapidly progressing blood cancer, and we are proud that its value has been recognised," said Eilis Quinn, the general manager of Jazz Pharmaceuticals for Australia and New Zealand.
'A valuable therapeutic option for patients with this complex, rapidly progressing blood cancer'
December 20, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Industry pushes back on conspiracy theories, highlighting the Government's own comments
March 22, 2025 - - Latest News -
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News